Mechanistic modeling of the pharmacokinetics and target engagement of tucatinib in patients with cancer also provides further evidence that tucatinib could induce sufficient HER2 inhibition not only in brain metastases with a disrupted BBTB, but potentially also in micrometastases where the BBTB is largely intact (48). This evidence concerns the gene ERBB2 and cancer.